Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved..
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with GC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
ESMO open - 9(2024), 2 vom: 06. Feb., Seite 102226 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shitara, K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ESMO |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 16.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.esmoop.2023.102226 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369483936 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369483936 | ||
| 003 | DE-627 | ||
| 005 | 20240316232925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240309s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2023.102226 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1332.xml |
| 035 | |a (DE-627)NLM369483936 | ||
| 035 | |a (NLM)38458658 | ||
| 035 | |a (PII)S2059-7029(23)01467-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shitara, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 16.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different Asian regions represented by the 10 oncological societies. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with GC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, whilst respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies, between the different regions of Asia | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a ESMO | |
| 650 | 4 | |a Pan-Asian | |
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a guidelines | |
| 650 | 4 | |a treatment | |
| 700 | 1 | |a Fleitas, T |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, H |e verfasserin |4 aut | |
| 700 | 1 | |a Curigliano, G |e verfasserin |4 aut | |
| 700 | 1 | |a Narita, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, F |e verfasserin |4 aut | |
| 700 | 1 | |a Wardhani, S O |e verfasserin |4 aut | |
| 700 | 1 | |a Basade, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rha, S Y |e verfasserin |4 aut | |
| 700 | 1 | |a Wan Zamaniah, W I |e verfasserin |4 aut | |
| 700 | 1 | |a Sacdalan, D L |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, M |e verfasserin |4 aut | |
| 700 | 1 | |a Yeh, K H |e verfasserin |4 aut | |
| 700 | 1 | |a Sunpaweravong, P |e verfasserin |4 aut | |
| 700 | 1 | |a Sirachainan, E |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, M-H |e verfasserin |4 aut | |
| 700 | 1 | |a Yong, W P |e verfasserin |4 aut | |
| 700 | 1 | |a Peneyra, J L |e verfasserin |4 aut | |
| 700 | 1 | |a Ibtisam, M N |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, K-W |e verfasserin |4 aut | |
| 700 | 1 | |a Krishna, V |e verfasserin |4 aut | |
| 700 | 1 | |a Pribadi, R R |e verfasserin |4 aut | |
| 700 | 1 | |a Li, J |e verfasserin |4 aut | |
| 700 | 1 | |a Lui, A |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, T |e verfasserin |4 aut | |
| 700 | 1 | |a Baba, E |e verfasserin |4 aut | |
| 700 | 1 | |a Nakayama, I |e verfasserin |4 aut | |
| 700 | 1 | |a Pentheroudakis, G |e verfasserin |4 aut | |
| 700 | 1 | |a Shoji, H |e verfasserin |4 aut | |
| 700 | 1 | |a Cervantes, A |e verfasserin |4 aut | |
| 700 | 1 | |a Ishioka, C |e verfasserin |4 aut | |
| 700 | 1 | |a Smyth, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 9(2024), 2 vom: 06. Feb., Seite 102226 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:2 |g day:06 |g month:02 |g pages:102226 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2023.102226 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 2 |b 06 |c 02 |h 102226 | ||